Vermillion Receives Notice of Allowance for Patent on Platelet Biomarkers of Angiogenesis
News Mar 06, 2012
Vermillion, Inc. has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Platelet biomarkers for cancer."
The patent resulted from a collaboration with the late Dr. Judah Folkman, a renowned cancer expert, and identifies three biomarkers that can be used to assess changes in endogenous angiogenesis in a subject.
Angiogenesis is commonly associated with cancer, and novel therapeutics such as bevacizumab (Avastin®) target angiogenesis to limit tumor recruitment of blood vessels.
The patented biomarkers, which are associated with platelets, can be used to measure ongoing angiogenic activity.
The patent covers the measurement of these biomarkers over time and correlating changes in expression with the changing level of endogenous angiogenic activity.
Consequently, this patent also enables the use of these biomarkers to monitor efficacy of therapy directed at angiogenic pathways.
"Vermillion is committed to the creation of innovative, effective tests for cancer diagnosis and patient management," said Dr. Donald Munroe, the company's chief scientific officer.
Dr. Munroe continued, "We believe the addition of this new angiogenic biomarkers patent to our already extensive IP portfolio could enable new methods of monitoring disease progression and therapeutic response."
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE
Protein That Helps Keep Breast Cancer Dormant IdentifiedNews
A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.READ MORE
Combination Chemotherapy Could Significantly Improve Deadly Brain Tumor TreatmentNews
A team led by Massachusetts General Hospital (MGH) investigators has found that adding the chemotherapy drug hydroxyurea to the current chemotherapy protocol for glioblastoma significantly increased survival in animal models.READ MORE